Biological basis for novel mesothelioma therapies
Azad, Arsalan A.
Rassl, Doris M.
Rintoul, Robert C.
British Journal of Cancer
Nature Publishing Group UK
MetadataShow full item record
Obacz, J., Yung, H., Shamseddin, M., Linnane, E., Liu, X., Azad, A. A., Rassl, D. M., et al. (2021). Biological basis for novel mesothelioma therapies. British Journal of Cancer, 125 (8), 1039-1055. https://doi.org/10.1038/s41416-021-01462-2
Funder: British Lung Foundation (BLF); doi: https://doi.org/10.13039/501100000351
Funder: Royal Society through a University Research Fellowship and the Engineering and Physical Sciences Research Council (EPRSC)
Funder: China Scholarship Council (CSC); doi: https://doi.org/10.13039/501100004543
Abstract: Mesothelioma is an aggressive cancer that is associated with exposure to asbestos. Although asbestos is banned in several countries, including the UK, an epidemic of mesothelioma is predicted to affect middle-income countries during this century owing to their heavy consumption of asbestos. The prognosis for patients with mesothelioma is poor, reflecting a failure of conventional chemotherapy that has ultimately resulted from an inadequate understanding of its biology. However, recent work has revolutionised the study of mesothelioma, identifying genetic and pathophysiological vulnerabilities, including the loss of tumour suppressors, epigenetic dysregulation and susceptibility to nutrient stress. We discuss how this knowledge, combined with advances in immunotherapy, is enabling the development of novel targeted therapies.
Review Article, /631/67/1641, /631/80/304, review-article
External DOI: https://doi.org/10.1038/s41416-021-01462-2
This record's URL: https://www.repository.cam.ac.uk/handle/1810/329314
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: email@example.com